Zacks Investment Research downgraded shares of ANTHERA PHARMA (ANTH) from OUTPERFORM to NEUTRAL on September 30, 2014, with a target price of $2.10.
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company's clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sj gren's Syndrome, Graves' Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward,
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on ANTHERA PHARMA (ANTH),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment